







INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 4 : C07D 473/18, 473/32, 473/34 A61K 31/52, 31/675, C07F 9/65	A1	(11) International Publication Number: WO 89/10923 (43) International Publication Date: 16 November 1989 (16.11.89)
(21) International Application Number: PCT/SE89/00255 (22) International Filing Date: 5 May 1989 (05.05.89) (30) Priority data: 8801729-8 6 May 1988 (06.05.88) SE (71) Applicant (for all designated States except US): MEDIVIR AB [SE/SE]; Statens Bakteriologiska Laboratorium, Lundagatan 2, S-105 21 Stockholm (SE). (72) Inventors; and (75) Inventors/Applicants (for US only) : LINDBORG, Björn, Gunnar [SE/SE]; Helgarögränd 14, S-125 42 Älvsjö (SE). DATEMA, Roelf [SE/US]; 511 Cardinal Lane, Cheshire, CT 06410 (US). JOHANSSON, Karl, Nils, Gunnar [SE/SE]; Bäverstigen 19, S-150 23 Enhörna (SE). ÖBERG, Bo, Fredrik [SE/SE]; Askvägen 27, S-752 52 Uppsala (SE).		(74) Agents: LARFELDT, Helene et al.; Bergenstråhle & Lindvall AB, Sankt Paulsgatan 1, S-116 47 Stockholm (SE). (81) Designated States: AU, DK, FI, HU, JP, KR, NO, US. Published <i>With international search report.</i>
(54) Title: DERIVATIVES OF PURINE, PROCESS FOR THEIR PREPARATION AND A PHARMACEUTICAL PREPARATION <div style="text-align: center;">  <p>(I)</p> </div> <div style="display: flex; justify-content: space-around; align-items: center;"> <div style="text-align: center;">  <p>(II)</p> </div> <div style="text-align: center;">  <p>(III)</p> </div> </div> <div style="text-align: center; margin-top: 20px;">  <p>(IV)</p> </div>		
(57) Abstract Antivirally active compounds of formula (I), wherein R ¹ is hydrogen, hydroxy, mercapto or amino; R ² is hydrogen, hydroxy, fluoro, chloro or amino; R ³ and R ⁴ are independently selected from (II), (III), amino, hydroxy or an ether or ester residue thereof, or R ³ together with R ⁴ is (IV), wherein M is hydrogen or a pharmaceutically acceptable counterion; and n is 1 or 2; with the proviso that, when R ² is amino and R ³ and R ⁴ are hydroxy, R ¹ is not hydroxy and in addition, when n = 1, R ¹ is not hydrogen, and pharmaceutically acceptable salts thereof; processes for preparation of said compounds, a pharmaceutical composition comprising said compounds, methods for treatment of virus infections as well as use of compounds of formula (I) without the proviso for the manufacture of a medicament for treatment of AIDS.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	FI	Finland	ML	Mali
AU	Australia	FR	France	MR	Mauritania
BB	Barbados	GA	Gabon	MW	Malawi
BE	Belgium	GB	United Kingdom	NL	Netherlands
BF	Burkina Fasso	HU	Hungary	NO	Norway
BG	Bulgaria	IT	Italy	RO	Romania
BJ	Benin	JP	Japan	SD	Sudan
BR	Brazil	KP	Democratic People's Republic of Korea	SE	Sweden
CF	Central African Republic	KR	Republic of Korea	SN	Senegal
CG	Congo	LI	Liechtenstein	SU	Soviet Union
CH	Switzerland	LK	Sri Lanka	TD	Chad
CM	Cameroon	LU	Luxembourg	TG	Togo
DE	Germany, Federal Republic of	MC	Monaco	US	United States of America
DK	Denmark	MG	Madagascar		
ES	Spain				

Derivatives of purine, process for their preparation and a pharmaceutical preparation.

Field of the invention

5 The present invention relates to novel and known chemical compounds and pharmaceutically acceptable salts thereof for use in therapy for therapeutic and prophylactic treatment of the acquired immuno deficiency syndrome (AIDS) and infections caused by viruses requiring reverse transcriptase for
10 replication, such as human immunodeficiency viruses and hepatitis B viruses, and also for treatment of other virus diseases, such as those of herpes viruses, diseases which include both common infections and neoplastic diseases, i.e. cancer.

15

Background of the invention

The effects of viruses on bodily functions is the end result of changes occurring at the cellular and subcellular levels.
20 The pathogenic changes at the cellular level are different for different combinations of viruses and host cells. While some viruses cause a general destruction (killing) of certain cells, other may transform cells into a neoplastic state.

25

Important common viral infections are herpes dermatitis (including herpes labialis), herpes keratitis, herpes genitalis, herpes zoster, herpes encephalitis, infectious mononucleosis and cytomegalovirus infections all of which
30 are caused by viruses belonging to the herpes virus group. Other important viral diseases are influenza A and B which are caused by influenza A and B virus respectively. Another important common viral disease is viral hepatitis and especially hepatitis B virus infections are widely spread.
35 Effective and selective antiviral agents are needed for treatment of these diseases as well as for other diseases caused by viruses.

Several different viruses of both DNA and RNA type have been

shown to cause tumors in animals. The effect of cancerogenic chemicals can on animals result in activation of latent tumor viruses. It is possible that tumor viruses are involved in human tumors. The most likely human cases shown today are
5 leukemias, sarcomas, breast carcinomas, Burkitt lymphomas, nasopharyngeal carcinomas and cervical cancers where RNA tumor viruses and herpes viruses are indicated. This makes the search for selective inhibitors of tumorogenic viruses and their functions an important undertaking in the efforts
10 to treat cancer.

In the late seventies a new disease was reported, which subsequently was referred to as Acquired Immuno Deficiency Syndrome (AIDS). It is now generally accepted that a
15 retrovirus referred to as HIV (Human Immunodeficiency Virus), formerly known as Human T-cell Lymphotropic Virus (HTLV-III) or Lymphadenopathy Associated Virus (LAV) plays an essential role in the etiology of AIDS. Different types of HIV have been found such as HIV-1 and HIV-2 and more are likely to be
20 isolated.

AIDS is characterized by a profound immunodeficiency due to low numbers of a subset of lymphocyte-T-helper cells, which are one target for HIV-infection. The profound
25 immunodeficiency in AIDS patients makes these patients highly susceptible to a variety of opportunistic infections of bacterial, fungal, protozoal or viral etiology. The etiological agents among viral opportunistic infections are often found in the herpes virus group, i.e. herpes simplex
30 virus (HSV), Varicella Zoster virus (VZV), Epstein-Barr Virus (EBV) and, especially, cytomegalovirus (CMV). Other retroviruses affecting animals are feline leukemia virus and equine infectious anaemia virus. Human diseases such as multiple sclerosis, psoriasis and Kawasaki disease have also
35 been reported to be associated with retrovirus infections.

Hepatitis B virus infections cause severe disease such as acute hepatitis, chronic hepatitis, fulminant hepatitis in a consider able number of persons. It is estimated that there

are 200 million patients with chronic hepatitis B infection in the world. A considerable number of the chronic cases progress to liver cirrosis and liver tumours. In some cases the hepatitis infections also take a rapid and severe course as in fulminant B hepatitis with about 90 % mortality. At present there is no known effective treatment against hepatitis B infections. The replication of hepatitis B virus is similar to that of retroviruses and it contains the same essential viral reverse transcriptase activity.

10

General outline of the invention

A great number of nucleoside analogues exhibit several antimetabolic activities. They do so by substituting for or competing with the naturally occurring nucleosides. Recently some nucleoside analogues have been described, which inhibit in cell culture the multiplication of human immunodeficiency virus (HIV, also called HTLV-III, LAV) the causative agent of AIDS and AIDS-related complex (ARC).

20

We have now found that activities for inhibition of HIV and/or herpes multiplication are exhibited by nucleoside analogues, in which the nucleoside bases are both natural and modified purine bases which in N-9 position are derivatized with an acyclic side chain, branched in the 2'-position, and containing functional groups.

25

Prior Art

Purine derivatives with antiviral activity have previously been disclosed in the following references:

30

9-(Phosphonylmethoxyalkyl)adenines are described in AU-A-56328/86 and AU-A-56468/86;

35


9-(1,3-dihydroxy-2-propoxymethyl)purines and cyclic phosphate esters are described in US-A-4,565,868, US-A-4-590,269 and EP-A-184 473; and

9-(4-hydroxy-3-hydroxymethylbutyl)purine derivatives are

described in EP-A-141 927.

In addition the compound of the formula


5



10

is known from EP-A-186 640;
and the compounds of the formula

15



20


wherein $n = 1$ or 2 , are known from EP-A-146 516.

25

Disclosure of the invention

It has been found according to the present invention that the
compounds of the formula

30



35

I


wherein:

R¹ is hydrogen, hydroxy, mercapto or amino;


R² is hydrogen, hydroxy, fluoro, chloro or amino;

R³ and R⁴ are independently selected from

5



10 or an ether or ester residue thereof, or



15

M is hydrogen or a pharmaceutically acceptable counterion;
and n is 1 or 2; and pharmaceutically acceptable salts
thereof, inhibit the multiplication of human immunodeficiency
virus (HIV). The compounds of the formula I are useful as
20 therapeutic and/or prophylactic agents in the control and
treatment of HIV virus infections in man.

In a more general aspect, the compounds of the formula I are
useful as therapeutic and/or prophylactic agents in the
25 control and treatment of infections caused by retroviruses
and hepatitis B virus in mammals and man.

All retroviruses, including HIV, require the enzyme reverse
transcriptase in their natural cycle of replication.

30

Hepatitis B virus (HBV) is a DNA virus with a unique circular
double-stranded DNA genome which is partly single-stranded.
It contains a specific DNA polymerase required for viral
replication. This DNA polymerase also acts as a reverse
35 transcriptase during the replication of HBV DNA via an RNA
intermediate.

The compounds of the formula I inhibit the activity of
reverse transcriptase of retroviruses including HIV as well

as the activity of DNA polymerase of hepatitis B virus.

Another important area of use for the compounds of the formula I is in the treatment of herpes virus infections.


5 Among the herpes viruses may be mentioned Herpes simplex type 1 and 2, varicella (Herpes Zoster), virus causing infectious mononucleosis (i.e. Epstein-Barr virus) and cytomegalovirus. Important diseases caused by herpes viruses are herpes dermatitis (including herpes labialis), herpes genitalis,
10 herpes keratitis, herpes encephalitis and herpes zoster.

Another possible area of use for the compounds of the present invention is in the treatment of cancer and tumors, particularly those caused by viruses. This effect may be
15 obtained in different ways, i.e. by inhibiting the transformation of virus-infected cells to a neoplastic state, by inhibiting the spread of viruses from transformed cells to other normal cells and by arresting the growth of virus-transformed cells.

20

The present invention relates to the use of a compounds of the formula I

25




30

wherein:

R¹ is hydrogen, hydroxy, mercapto or amino;

35 R² is hydrogen, hydroxy, fluoro, chloro or amino;

R³ and R⁴ are independently selected from



or an ether or ester residue thereof, or

5

R^3 together with R^4 is $\begin{array}{c} \text{O} \\ \parallel \\ -\text{P}-\text{O}- \\ | \\ \text{OM} \end{array}$, wherein

M is hydrogen or a pharmaceutically acceptable counterion;
and n is 1 or 2; and pharmaceutically acceptable salts

10 thereof for the manufacture of a medicament for therapeutic
and/or prophylactic treatment of the acquired immuno
deficiency syndrome and infections caused by viruses
requiring reverse transcriptase for replication.


15 Preferably they can be used for the treatment of infections
caused by HIV viruses or hepatitis B virus.

The compounds of the formula I contain one asymmetric center
when $\text{CH}_2\text{CH}_2\text{R}^3$ and $(\text{CH}_2)_n\text{R}^4$ are different. Accordingly they
20 exist in two optical forms which constitute a further aspect
of the invention.

Preferred compounds to be used in accordance with the
invention are those wherein R^1 and R^2 are independently
25 hydrogen, hydroxy or amino and wherein R^3


is $\begin{array}{c} \text{O} \\ \parallel \\ -\text{P}(\text{OM})_2 \end{array}$, hydroxy or an ester derivative thereof, and R^4 is
OH or an ester derivative thereof or wherein R^3 and R^4
together are

30



Preferably R^3 and R^4 are both hydroxy.

35 Examples of especially preferred compounds are those of the
formula I



10

wherein

 $R^1 = \text{OH}, \quad R^2 = \text{NH}_2, \quad R^3 = \text{OH}, \quad R^4 = \text{OH}$
 $R^1 = \text{H}, \quad R^2 = \text{NH}_2, \quad R^3 = \text{OH}, \quad R^4 = \text{OH}$
 $R^1 = \text{NH}_2, \quad R^2 = \text{H}, \quad R^3 = \text{OH}, \quad R^4 = \text{OH}$

15

 $R^1 = \text{OH}, \quad R^2 = \text{NH}_2, \quad R^3 \text{ and } R^4 = \begin{array}{c} \text{O} \\ \parallel \\ -\text{P}-\text{OM} \\ | \\ -\text{O}- \end{array}$

20

 $R^1 = \text{H}, \quad R^2 = \text{NH}_2, \quad R^3 \text{ and } R^4 = \begin{array}{c} \text{O} \\ \parallel \\ -\text{P}-\text{OM} \\ | \\ -\text{O}- \end{array}$
 $R^1 = \text{NH}_2, \quad R^2 = \text{H}, \quad R^3 \text{ and } R^4 = \begin{array}{c} \text{O} \\ \parallel \\ -\text{P}-\text{OM} \\ | \\ -\text{O}- \end{array}$

25

 $R^1 = \text{OH}, \quad R^2 = \text{NH}_2, \quad R^3 = \text{OCOC}_{1-3}, \quad R^4 = \text{OCOC}_{1-3}$
 $R^1 = \text{H}, \quad R^2 = \text{NH}_2, \quad R^3 = \text{OCOC}_{1-3}, \quad R^4 = \text{OCOC}_{1-3}$
 $R^1 = \text{NH}_2, \quad R^2 = \text{H}, \quad R^3 = \text{OCOC}_{1-3}, \quad R^4 = \text{OCOC}_{1-3}$
 $R^1 = \text{OH}, \quad R^2 = \text{NH}_2, \quad R^3 = \text{OCONH-phenyl}, \quad R^4 = \text{OCONH-phenyl}$

30

 $R^1 = \text{H}, \quad R^2 = \text{NH}_2, \quad R^3 = \text{OCONH-phenyl}, \quad R^4 = \text{OCONH-phenyl}$
 $R^1 = \text{NH}_2, \quad R^2 = \text{H}, \quad R^3 = \text{OCONH-phenyl}, \quad R^4 = \text{OCONH-phenyl}$

Esters and ethers of the purine derivatives are also included in the invention. Examples of esters are phosphate esters, carboxylic esters, carbonate esters, carbamate esters or sulphonic esters. The acid part of the esters may have alkyl, aryl or arylalkyl chains, where the aryl functionalities are optionally substituted for example by alkoxy, amino, nitrile, alkyl or sulphonamido groups or by one or more halogen atoms.

35

- Examples of other types of derivatives of the purine bases are alkyl or arylalkyl derivatives of the primary hydroxyl group(s). The arylalkyl ether derivatives may be for example benzyl or triphenyl methyl and the aryl moiety may be optionally substituted. Furthermore, it is understood that the examples of the pharmaceutically acceptable salts cited below also apply to the various esters or derivatives of the purine bases of the invention.
- 10 In a compound of the formula I R^3 and R^4 as an ether residue can be defined as OR^5 , wherein R^5 is C_{1-6} alkyl, arylalkyl optionally substituted with one or more alkoxy, amino, nitrile or sulphamido groups or one or more halogen atoms.
- 15 R^3 and R^4 as an ester residue can be derived from a carboxylic acid R^6COOH , a carbonic acid R^7OCOOH , a double ester of a carbonic acid $R^7CO_2CH(R^8)OCO_2H$, a sulphonic acid R^7SO_2OH , a carbamic acid $R^7NHCOOH$ or a phosphoric acid, wherein R^6 is hydrogen, C_{1-17} alkyl, alkoxyalkyl, arylalkyl or aryl, R^7 is C_{1-17} alkyl, arylalkyl or aryl, R^8 is hydrogen or C_{1-3} alkyl and said aryl and arylalkyl groups optionally can be substituted with one or more alkyl, alkoxy, amino, nitrile, sulphonamide groups or one or more halogen atoms.
- 25 Examples of pharmaceutically acceptable salts of the compounds of formula I include base salts, e.g. derived from an appropriate base, such as alkali metal (e.g. sodium, potassium, alkaline earth metal (e.g. magnesium) salts, ammonium and NX_4^+ (wherein X is C_{1-4} alkyl). Physiologically
- 30 acceptable acid salts include salts of organic carboxylic acids such as acetic, lactic, gluconic, citric, tartaric, maleic, malic, pantothenic, isethionic, oxalic, lactobionic and succinic acids; organic sulfonic acids such as methanesulfonic, ethanesulfonic, benzenesulfonic, p-
- 35 chlorobenzenesulphonic and p-toluenesulfonic acids and inorganic acids such as hydrochloric, hydroiodic, sulfuric, phosphoric and sulfamic acids.


Physiologically acceptable counterions of the phosphonate

groups include inorganic and organic counterions. Inorganic counterions are for example ammonium, sodium, potassium, lithium, magnesium and calcium. Organic counterions are derived from non-toxic bases, such as primary, secondary and tertiary amines, including naturally occurring amines. Examples of such amines are diethylamine, triethylamine, isopropylamine, ethanolamine, morpholine, 2-diethylaminoethanol, glucosamine, N-methylglucamine, piperazine and dicyclohexylamine.

10

The present invention also relates to novel compounds of the formula

15




20

wherein:


- R^1 is hydrogen, hydroxy, mercapto or amino;
 R^2 is hydrogen, hydroxy, fluoro, chloro or amino;
 R^3 and R^4 are independently selected from

30



or an ether or ester residue thereof, or

R^3 together with R^4 is



, wherein

M is hydrogen or a pharmaceutically acceptable counterion;
and n is 1 or 2; with the proviso that, when R² is amino and
R³ and R⁴ are hydroxy, R¹ is not hydroxy and in addition,
5 when n = 1, R¹ is not hydrogen, and pharmaceutically
acceptable salts thereof.

The invention furthermore provides:

10. A pharmaceutical composition comprising a new compound of the
formula I as active ingredient; and

A method for therapeutic and/or prophylactic treatment of
virus infections in an animal or human host in need of
15 treatment comprising administering an effective amount of a
new compound of the formula I.

It is a preferred aspect of the invention to treat infections
caused by herpes virus or a virus requiring reverse
20 transcriptase for replication; including human immuno
deficiency viruses and hepatitis B virus.

In clinical practice the purine derivatives of the formula I
will normally be administered orally, by injection or by
25 infusion in the form of a pharmaceutical preparation
comprising the active ingredient in the form of the original
compound or optionally in the form of a pharmaceutically
acceptable carrier which may be a solid, semi-solid or liquid
diluent or an ingestible capsule. The compound may also be
30 used without carrier material. As examples of pharmaceutical
preparations may be mentioned tablets, dragées, capsules,
granulates, suspensions, elixirs, syrups, solutions etc.
Usually the active substance will comprise between 0.05 and
20 % for preparations intended for injection and between 10
35 and 90 % for preparations intended for oral administration.

In the treatment of patients suffering from retrovirus,
especially HIV, or hepatitis B virus infections, it will be
preferred to administer the compounds by any suitable route

including the oral, parenteral, rectal, nasal, topical and vaginal route. The parenteral route includes subcutaneous, intramuscular, intravenous and sublingual administration. The topical route includes buccal and sublingual administration.

5 The dosage at which the active ingredients are administered may vary within a wide range and will depend on various factors such as the severity of the infection, the age of patient etc., and may have to be individually adjusted. As a possible range for the amount of the compounds of the

10 invention or a physiologically acceptable salt thereof to be administered per day may be mentioned from about 10 mg to about 10 000 mg, preferentially 100-500 mg for intravenous administration and preferentially 100-3000 mg for oral administration.

15

Compounds of the formula I can cooperate synergistically or additively with a wide range of other therapeutic agents, thereby enhancing the therapeutic potential of both agents without adding the toxic effects, thus increasing the

20 therapeutic ratio.

Therefore, a compound of formula I or a pharmaceutically acceptable derivative thereof can be used in combination therapy, wherein the two active agents are present in a ratio

25 resulting in an optimal therapeutic ratio. This can be provided either by a synergistic effect against the viral infection and/or by a decrease in toxicity while maintaining a therapeutic effect which is additive or synergistic.

30 The optimal therapeutic ratio is observed when the two agents are present in a ratio of 500:1 to 1:500, preferably 100:1 to 1:100, particularly 20:1 to 1:20 and especially 10:1 to 1:10.

Said combinations may conveniently be administered together,

35 for example, in a unitary pharmaceutical formulation, or separately for example as a combination of tablets and injections administered at the same time or different times, in order to achieve the required therapeutic effect.

The compounds of the formula I are potentiated by interferons, other antiviral agents such as foscarnet, AZT, HIV protease inhibitors, immunomodulators, interferon inducers and growth factors.

5

Particularly preferred types of interferon are α , β and γ and interferon inducers such as "Ampligen" (Hem Research).

Other combinations suitable for use according to the present invention include those wherein the second agent is, for example, interleukin II, suramin, foscarnet or an ester thereof, HPA 23, inhibitors of HIV protease such as pepstatin, steroids, medications such as levamisol or thymosin to increase lymphocyte numbers and/or function as appropriate, or GM-CSF and other factors regulating cell functions.


Methods of preparation

20 The compounds of the invention may be prepared by one of the following general methods, constituting a further aspect of the invention.

A. Condensing an acyclic side chain as comprised in formula I, to the N-9 position of a purine derivative. The acyclic side chain has a terminal leaving group and the functional groups may be optionally protected with known groups used for protection of hydroxy, amino or phosphonate functions.


30

35



5


10



- 15 Examples of suitable derivatives of the reacting species are those wherein R^1 is Cl, or R^1 as defined above, R^2 , R^3 , R^4 and n are as defined above, and W is a suitable leaving groups, such as Cl, Br, J, alkyl or aryl sulfonyloxy, trifluoromethanesulfonyloxy. The condensation reaction is
- 20 performed in an organic solvent such as dimethyl formamide, dimethylsulfoxide, ethanol, acetonitrile, dichloromethane or the like at a temperature of between 0°C and 150°C for 1 hour to 5 days, and after condensation the products may be hydrolyzed or converted by conventional methods, known to
- 25 those skilled in the art, into compounds of the formula I.


For the case of a phosphonate the side chains condensed to a purine base could be prepared in different ways. One example is the following reaction sequence, where the starting

30 material 5-(2-bromoethyl)-2,2-dimethyl-1,3-dioxane has been described (M.R. Harnden and R.L. Jarvest, Tetrahedron Letters, Vol. 26, pages 4265-4268, 1985).



a) $P(OMe)_3$; B) H^+ , MeOH; c) MeO^- ; d) N-bromosuccinimide, triphenylphosphine;


- 5 B. Imidazole ring closure of a substituted pyrimidine derivative to the purine base followed by removal of the protecting groups.



R^1 , R^2 , R^3 and R^4 are as defined above, R^{10} is nitroso, nitro, amino or an amino derivative such as formylamino or orthoesteramino. The ring closure may be performed by known methods (the principles which are given for example by E. Lunt in Comprehensive Organic Chemistry (Eds. D. Barton and W.B. Ollis, Pergamon Press 1979) vol 4, p. 499-505 and by G. Shaw in Comprehensive Heterocyclic Chemistry (Eds. A.R. Katritzsky and C.W. Reese, Pergamon Press 1984) vol. 5, p. 570-573. The reaction may be performed in an organic solvent such as for example, formic acid, formamide, orthoformate ester or diethoxymethylacetate at a temperature from 25°C to 250°C for 10 minutes to 24 hours. When R^{10} is nitroso or


nitro, these groups first have to be reduced to an amino group by any known method.

- C. Imidazole ring closure via a furazano[3,4-d]pyrimidine ring system to the purine base followed by removal of the protecting groups.



R^2 , R^3 and R^4 are as defined above. The ring closure may be performed by heating following reductive cleavage of the furazane ring by for example zinc in acetic acid. After reaction the 6-NH₂ group of the purine may optionally be transformed to a hydroxy group by treatment with for example sodium nitrile in acetic acid.

- D. Pyrimidine ring closure to the purine base followed by removal of the protecting groups.




The ring closure may be performed according to known methods which have been described for example by G. Shaw in Comprehensive Heterocyclic Chemistry (Eds. A.R. Katritzsky and C.W. Reese, Pergamon Press 1984) Vol. 5, p. 583-591 and by E. Lunt in Comprehensive Organic Chemistry (Eds. D. Barton and W.B. Ollis, Pergamon Press 1979) Vol. 4, p. 505-508.

The described methods A-D may be used to give mixtures of optical isomers, or in appropriate cases a single optical isomer. A compound according to the invention in the form of an optical isomer can be prepared if in method A either an optically active acyclic side chain is condensed to the N-9 position of the purine derivative or the condensation is directed to the formation of an optical isomer by means of another optically active compound, and in methods B-D starting materials having an optically active side chain are subjected to the ring closure. Additionally a single optical isomer may be obtained from the racemic mixtures by methods

known per se.

The following examples will further illustrate the invention.

5 Example 1 2-(2-Aminopurin-9-yl)methyl butan-1,4-diol



VSB 212

To a solution of crude dimethyl (2-aminopurin-9-ylmethyl)
succinate (3.2 g, 10.9 mmol), dissolved in tert. butanol (250
ml) at 40°C, was added lithium borohydride (1.3 g, 60 mmol)
20 in portions with stirring. After 1 hour at ambient
temperature, water (30 ml) was added slowly and stirring
continued over night. Inorganic salts were filtered and the
solution evaporated to dryness. Yield of crude product was
1.6 g (50 %). Chromatography on silica (chloroform + methanol
25 7+1) afforded pure product.

¹H NMR (DMSO-d₆): δ 31.4 (m, 2H) CH₂CH₂OH; 2.14 (m, 1H) CH;
3.33 (d, 2H) CH-CH₂OH; 3.44 (diffuse q, 2H); 4.05 (AB part of
ABX, 2H) N-CH₂; 6.37 (broad s, 2H) NH₂; 7.99 (s, 1H) H8; 8.56
30 (s, 1H) H6.

¹³C NMR (D₂O): δ 33.11 CH₂CH₂OH; 39.58 CH; 46.34 NCH₂; 61.35
and 63.51 2xCH₂OH; 128.41 C5; 146.92 C8; 150.48 C6; 155.05
C4; 161.50 C2.

35 The starting material dimethyl 2-(2-aminopurin-9-ylmethyl)
succinate was prepared as follows (a,b):

a) Dimethyl 2-(2-amino-6-chloropurin-9-ylmethyl)-succinate


A mixture of 2-amino-6-chloropurine (4.07 g, 0.024 mol), dimethyl itaconate (5.00 g, 0.032 mol), and sodium hydride (55 % in oil, 0.2 g) in 50 ml of dry dimethylformamide was stirred at room temperature for 3 days. About 50 ml of water was added and the mixture was washed with n-hexane (2x50 ml) and then extracted with 2x50 ml of dichloromethane. The combined CH_2Cl_2 extracts were washed with 2x20 ml of water, dried with magnesium sulfate, and evaporated in vacuum. Treatment with ether and drying afforded a white crystalline product. Chromatography (silica gel, chloroform + methanol 15+1) yielded 5.54 g (71 %) or recrystallization ($\text{MeOH-H}_2\text{O}$) yielded 5.15 g (66.1 %) of dimethyl 2-(2-amino-6-chloropurin-9-ylmethyl)succinate. UV spectrum in EtOH, λ_{max} (nm): 310 (247).

^1NMR (CDCl_3) δ 2.67 (dd, 2H) CH_2COO ; 3.46 (m, 1H) CH; 3.70 (2s, 2x3H) OCH_3 ; 4.42 (ABX system, $J_{\text{gem}} = 14$ Hz, 2H) NCH_2 ; 5.35 (broad s, 2H) NH_2 ; 7.79 (s, 1H) H8.

b) Dimethyl 2-(2-aminopurin-9-ylmethyl)succinate

A mixture of dimethyl 2-(2-amino-6-chloropurin-9-ylmethyl)succinate (3.28 g, 10 mmol), sodium acetate (1.5 g) and 5 % palladium on charcoal (0.4 g) in ethanol (200 ml) was hydrogenated with agitation in a Parr apparatus at 40 psi for 115 h/room temperature. After filtration, sodium acetate (1.6 g) and 5 % Pd/C (0.4 g) were added and the hydrogenation was continued for 70 h. After filtration and evaporation to dryness, the residue was extracted with 2x50 ml of chloroform and the combined extracts were evaporated to dryness affording 2.6 g (89 %) of crude dechlorinated product. $^1\text{H NMR}$ (DMSO-d_6) δ 8.00 (s, 1H) H8; 8.56 (s, 1H) H6.

Example 2 2-(2-Aminopurin-9-yl)methylbutane-1,4-diol diacetate



5
10
15
A mixture of 4-acetoxy-2-bromomethylbutyl acetate (0.465 g, 1.74 mmol), 2-aminopurine (0.282 g, 2.09 mmol), and powdered potassium carbonate (1.20 g, 8.70 mmol) in N,N-dimethylformamide (20 ml) was stirred at room temperature for 5 days. Chloroform (40 ml) was added, solid material was removed by filtration, and the solution was evaporated in vacuum to small volume. Chromatography on 50 g SiO₂ with chloroform + methanol (7+1) as eluent gave a fraction 70-130 ml, which was evaporated and dried in vacuum, finally at 0.1 mBar to give 0.349 g (62 %) of 2-(2-aminopurin-9-yl)methylbutane-1,4-diol diacetate. TLC on silica (chloroform + methanol 7+1): R_f 0.57.

20
25
¹H NMR (CDCl₃+CD₃OD): δ 8.64 (s, 1H) H6; 7.92 (s, 1H) H8; 5.82 (broad s, 2H) NH₂; 4.3-4.15 (m, 4H) 2 CH₂OAc; 4.33 (d, 2H) CH₂N; 2.50 (m, 1H) CH; 2.06 (s, 6H) 2 CH₃COO; 1.75 (q, 2H) CH₂CH₂OAc; ¹³C NMR (CDCl₃+CD₃CD): δ 170.96, 170.66 (2 C=O); 159.89 (C2); 153.13 (C4); 148.77 (C6); 142.84 (C8); 126.83 (C5); 63.78 (CHCH₂-OAc); 61.47 (CH₂CH₂OAc); 44.05 (CH₂N); 35.15 (CH); 27.59 (CH₂CH₂O); 20.22, 20.05 (2 CH₃).

The starting materials were prepared by the following sequence of reactions (a-e):

30 a) α-Trityloxymethyl-γ-butyrolactone

A mixture of α-hydroxymethyl-γ-butyrolactone (26.83 g, 0.231 mol) (G. Claeson and H.-G. Jonsson, Arkiv för Kemi 28, 167 (1967)), trityl chloride (77.3 g, 0.277 mol) and dry pyridine (200 ml) was stirred at room temperature for a few hours until homogeneous. After 10 days at room temperature the solution was poured into a mixture of 500 ml water and 500 ml n-hexane. The precipitate was washed with water and hexane and dried finally at 0.1 mBar to give 65.60 g (79 %) of crude product, contaminated with some trityl alcohol. TLC on silica

(ethyl acetate + n-hexane 1+3): R_f 0.38.

^{13}C NMR (CDCl_3): δ 177.84 (C=O); 143.71, 128.68, 127.96 and 127.20 (phenyl); 86.96 (O CPh_3); 67.26 (CH_2OCO); 62.49 (CH_2OTr); 40.31 (CH); 26.15 ($\text{CH}_2\text{CH}_2\text{O}$).

5

b) 2-Trityloxymethyl-1,4-butanediol

α -Trityloxymethyl- γ -butyrolactone (60.21 g, 0.168 mol) was added in small portions to a stirred suspension of lithium aluminium hydride (9.53 g, 0.251 mol) in dry tetrahydrofuran (300 ml) and the mixture was refluxed for 1 h. Slow addition of 10 ml H_2O + 10 ml 15 % NaOH and 30 ml H_2O produced a white sandy precipitation which was filtered off and washed with 2x50 ml tetrahydrofuran. The filtrate was evaporated to a small volume and dissolved in diethyl ether (300 ml), silica gel (250 g) was added and the mixture was carefully evaporated to a homogeneous powder. In a chromatography column the crude product - silica gel mixture was placed on top of silica gel (250 g) in n-hexane. Eluting with ethyl acetate + n-hexane (1+3), 2200 ml, removed trityl alcohol. Further eluting with ethyl acetate + ethanol (9+1) gave fractions 2900-3700 ml (from start), which after evaporation in vacuum produced a crystallizing oil. Yield 52.77 g (87 %). TLC on silica: ethyl acetate + n-hexane (1+3), R_f 0.05; ethyl acetate + ethanol (9+1), R_f 0.81.

25

c) 2-Trityloxymethyl-1,4-butanediol diacetate

To a stirred mixture of 2-trityloxymethyl-1,4-butanediol (50.85 g, 0.140 mol) and triethylamine (42.6, 0.42 mol) in dry diethyl ether (500 ml) was added slowly a solution of acetyl chloride (27.5 g, 0.35 mol) in ether (25 ml) with external cooling with cold water to maintain room temperature in the mixture. After 45 min the triethylamine hydrochloride was filtered off and washed with a little ether. The combined filtrate was washed with water (50 ml), 0.5 M hydrochloric acid (100 ml) and water (50 ml), dried with magnesium sulfate and evaporated in vacuum, finally at 0.1 mBar, to give 61.03 g (97 %) of crude oily product. TLC on silica (ethyl acetate

30

35

+ n-hexane 1+1): R_f 0.68.

d) 4-Acetoxy-2-hydroxymethylbutyl acetate

5 2-Trityloxymethyl-1,4-butanediol diacetate (60.90 g, 0.136 mol) was dissolved in acetic acid (320 ml) at 100°C and water, (80 ml) was added. The solution was kept at 100°C for 15 min, evaporated in vacuum to small volume and cooled to 0°C. The precipitate was filtered off and washed with cold ethyl acetate to give 26.44 g (theory 35.51 g) of trityl alcohol. The combined filtrate was evaporated to small volume. The compound was purified on a silica gel column (500 g SiO_2); eluent 0-2700 ml ethyl acetate + n-hexane (1+1), 2700-3740 ml ethyl acetate + n-hexane (2+1), then neat ethyl acetate. The fractions 2540-4800 ml were evaporated to give 14.20 g (51 %) of pure 4-acetoxy-2-hydroxy-methylbutyl acetate. TLC on silica (ethyl acetate + n-hexane 1+1): R_f 0.30.

^{13}C NMR (CDCl_3): δ 171.08, 170.88 (2 C=O); 64.07 (CH_2OH); 62.10, 61.45 (2 CH_2OAc); 37.07 (CH); 26.76 ($\text{CH}_2\text{CH}_2\text{OAc}$); 20.39 (2 CH_3).

e) 4-Acetoxy-2-bromomethylbutyl acetate

25 A solution of 4-acetoxy-2-hydroxymethylbutyl acetate (11.04 g, 0.054 mol) and triphenylphosphine (21.27 g, 0.081 mol) in dry dichloro methane (150 ml) was stirred at 0°C, and N-bromo-succinimide (14.43 g, 0.081 mol) was added in portions. The mixture was kept at 0°C for 20 h, evaporated to small volume and stirred with 50 ml of ethyl acetate + n-hexane (1+1). The white triphenylphosphine oxide was filtered off and washed with a little ethyl acetate + n-hexane (1-1). The combined filtrate was evaporated and purified on a 200 g SiO_2 column with ethyl acetate + n-hexane (1+1) as eluent. The 250-550 ml fraction was evaporated in vacuum to give 11.90 g (82 %) of pure 4-acetoxy-2-bromomethylbutyl acetate. TLC on silica (ethyl acetate + n-hexane 1+1): R_f 0.59.

^1H NMR (CDCl_3): δ 4.2-4.0 (m, 4H) 2 CH_2OAc ; 3.53 (ABX system, 2H) CH_2Br ; 2.25-2.1 (m, 1H) CH; 2.08, 2.06 (2 s, 2x3H) 2


COCH₃; 1.79 (m; 2H) CH₂CH₂OAc.

¹³C NMR (CDCl₃): δ 170.91, 170.74 (2 C=O); 64.90 (CHCH₂OAc); 61.71 (CH₂CH₂OAc); 36.56 (CH); 34.74 (CH₂Br); 28.88 (CH₂CH₂O); 20.95 (2CH₃).

5

Example 3 9-(4-Acetoxy-2-acetoxymethylbutyl)guanine
[2-(guanin-9-ylmethyl)-1,4-butanediol
diacetate]

10



VSA 639

15

A mixture of 9-(4-hydroxy-2-hydroxymethylbutyl)guanine (0.50 g, 2.0 mmol), acetic anhydride (1.02 g, 10.0 mmol), pyridine (1.11 g, 14.0 mmol), and dry N,N-dimethylformamide (25 ml) was stirred at room temperature for 13 days and then evaporated to dryness in vacuum. The crystalline residue was heated with 10 ml of water and lyophilized and recrystallized from water to give 0.468 g (69 %) of 9-(4-acetoxy-2-acetoxymethylbutyl)guanine.


¹³C NMR (CDCl₃+CD₃OD): δ 64.15 (CHCH₂O); 61.98 (CH₂CH₂O); 44.71 (CH₂N); 35.88 (CH); 27.95 (CH₂CH₂O); 20.87, 20.68 (2 CH₃).

30

Example 4 9-(4 Propionoxy-2-propionoxymethylbutyl)guanine
[2-(guanin-9-ylmethyl)-1,4-butanediol
dipropionate]


35

5



VSC 637

10




A mixture of 9-(4-hydroxy-2-hydroxymethylbutyl)guanine (0.50 g, 2.0 mmol), propionic anhydride (1.56 g, 12.0 mmol), pyridine (1.27 g, 16.0 mmol), and dry N,N-dimethylformamide (25 ml) was stirred at room temperature for 14 days and then evaporated to dryness in vacuum. The crystalline residue was heated with 10 ml of water and lyophilized and recrystallized from water to give 0.418 g (57 %) of 9-(4-propionyloxy-2-propionyloxymethylbutyl)-guanine.

^{13}C NMR ($\text{CDCl}_3 + \text{CD}_3\text{OD}$): δ 64.00 (CHCH_2O); 61.86 ($\text{CH}_2\text{CH}_2\text{O}$); 44.78 (CH_2N); 35.95 (CH); 28.00 ($\text{CH}_2\text{CH}_2\text{O}$); 27.56, 27.44 (2 $\text{CH}_3\text{CH}_2\text{CO}$); 9.00 (2 CH_3).


Example 5 (-)-9-(4-Hydroxy-2-hydroxymethylbutyl)guanine

30



VSB 647

35



A solution of (-)-2-(2-amino-6-chloropurin-9-ylmethyl)-1,4-butanediol (11.5 mg, 0.0423 mmol) in 50 % aqueous formic acid (0.75 ml) was kept at 100°C/2 h and then evaporated to dryness, dissolved in 2 ml of water and lyophilized. The product was dissolved in 1 ml of water, 2 drops of conc. aqueous ammonia was added and the solution kept at 100°C for 10 min, flushed with nitrogen to remove ammonia, and lyophilized. The residue was dissolved by warming with 1.2 ml of 20 % aqueous methanol and the solution filtered and kept in open air to allow for slow partial evaporation of solvent. Crystalline needles were formed. Filtration, washing with 3 drops of water and drying yielded 6.4 mg (60 %) of (-)-9-(4-hydroxy-2-hydroxymethylbutyl)guanine.

The compound was found to be levorotatory (ethanol, 589 and 546 nm). It produced a proton NMR (DMSO-d₆) identical to that of the racemate. TLC on silica (ethyl acetate + methanol + water 7+2+1): R_f 0.37, identical to that of the racemate.

The starting material was prepared as follows (a-b):

a) (-)-Dimethyl-2-(2-amino-6-chloropurin-9-ylmethyl)succinate


The racemic compound was resolved by repeated chromatography on a microcrystalline triacetylcellulose column, (Perstorp Biochem, Lund, Sweden) with 95 % ethanol as mobile phase. The slower moving (-)-enantiomer produced a proton NMR spectrum identical to that of the racemic compound (±). The resolution was followed by proton NMR in deuteriochloroform at 200 MHz with tris-[3-(heptafluoropropylhydroxymethylene)-d-camphorato]-europium(III) as chiral shift reagent. By addition of 1-1.5 parts (per weight) of shift reagent, the methyl ester signal of the racemate (2 close singlets at 3.69 and 3.695 ppm) were split into one base-line separated low-field pair (low-field signal from the (+)-enantiomer high-field signal from the (-)-enantiomer) and one less resolved high-field pair. The enantiomeric excess was then calculated from the ratio of the low-field signals.

b) (-)-2-(2-Amino-6-chloropurin-9-ylmethyl)-1,4-butanediol

To a solution of (-)-dimethyl-2-(2-amino-6-chloropurin-9-ylmethyl)succinate (enantiomeric excess 85 %; 19.9 mg, 0.0607 mmol), dissolved in tert. butanol (2.0 ml) at 40°C, was added lithium borohydride (30 mg, 1.38 mmol) in portions with stirring. After 1 h at ambient temperature, water (0.3 ml) was added slowly and stirring continued over night. Inorganic salts were filtered, washed carefully with tert. butanol and the solution was evaporated to dryness. Preparative thin-layer chromatography (PSC-Fertigplatten, Merck) with chloroform + methanol (5+1) as mobile phase afforded 16.5 mg (theoretical yield) of (-)-2-(2-amino-6-chloropurin-9-ylmethyl)-1,4-butanediol. $[\alpha]_D^{20} = -5.20^\circ$, $[\alpha]_{546}^{20} = -5.92^\circ$ (c 0.625, ethanol). TLC on silica (chloroform + methanol 5+1): R_f 0.40, identical to that of the racemate.

Example 6

9-(4-Hydroxy-2-hydroxymethylbutyl)adenine



VSC 600

Dimethyl 2-(adenine-9-ylmethyl)succinate (2.93 g, 0.010 mol) was dissolved by warming with tert. butanol (120 ml), lithium borohydride (1.10 g, 0.05 mol) was added in portions and the mixture was stirred at ambient temperature for 3 h, water (10 ml) was added and stirring was continued over night. Inorganic material was filtered off and washed with tert. butanol and the filtrate evaporated to small volume. Chromatography on silica (ethyl acetate + methanol + water 7+2+1) afforded pure 9-(4-hydroxy-2-hydroxymethylbutyl)

adenine.

^{13}C NMR ($\text{DMSO}-d_6$): δ 156.24 (C6); 152.67 (C2); 150.14 (C4); 141.84 (C8); 118.88 (C5); 61.18, 58.92 (2 CH_2OH); 44.81 (CH_2N); 38.36 (CH); 32.02 ($\text{CH}_2\text{CH}_2\text{OH}$).

5

The starting material was prepared as follows:

Dimethyl 2-(adenin-9-ylmethyl)succinate

10 A mixture of adenine (5.40 g, 0.040 mol), dimethyl itaconate (8.00 g, 0.051 mol), sodium hydride (55 % in oil, 0.2 g) and dry N,N-dimethylformamide (125 ml) was warmed to 120°C and then kept with stirring at room temperature for 8 days. The precipitate was filtered, washed with dichloromethane (3x15
15 ml) and dried in vacuum to yield 8.96 g (76 g) of dimethyl 2-(adenin-9-ylmethyl)-succinate.

^1H NMR (CDCl_3): δ 8.28 (s, 1H) H2; 7.90 (s, 1H) H8; 4.54 (ABX system 2H) CH_2N ; 3.70, 3.69 (2 s, 2x3H) OCH_3 ; 3.46 (m, 1H)

20 CH; 2.72 (d, 2H) CH_2COO .

^{13}C NMR ($\text{CDCl}_3+\text{CD}_3\text{OD}$): δ 172.39, 171.42 (2 C=O); 155.61 (C6); 152.91 (C2); 149.87 (C4); 141.01 (C8); 118.85 (C5); 52.37, 51.94 (OCH_3); 44.10 (CH_2N); 41.55 (CH); 33.30 (CH_2COO).


25

30

35

Example 7 Sodium ethyl 3-(guanin-9-ylmethyl)-4-hydroxybutanephosphonate and 7 isomer

VSC 658




2-Amino-6-chloro-9-[(2-ethoxy-2-oxo-1,2-oxaphosphorinan-5-yl)-methyl]purine (VSC 655) and its 7 isomer (100 mg, 0.29 mmol), dissolved in ethanol (4 ml), water (4 ml), and 2M aqueous sodium hydroxide (0.90 mmol) was kept at 37°C for 18 h. The solution was neutralized by addition of weakly acidic Amberlite cation exchange resin, filtered, and evaporated to dryness to give 113 mg (quantitative yield) of a crude product.

¹H NMR (D₂O, tert BuOH, 200 MHz): δ 8.01 and 7.79 (s, 8H, 7 and 9 isomers); ~4.03 (m, CH₂N); 3.78 (quintet, CH₂OP); 3.50 (d, CH₂OH); 2.05 and 1.6-1.3 (m, PCH₂CH₂CH); 1.12 (t, CH₃C-O-P).

¹³C NMR (D₂O, tert. BuOH, 50 MHz): δ 161.81, 160.47, 154.12, 145.5, 142.13, 114.55, 61.74/61.42 (CH₂OP); 45.35 and 45.15 (CH₂N); 42.25/41.91 (CH); 25.59, 22.89; 16.83 (CH₃C-O-P).

Example 8 Disodium 3-(guanin-9-ylmethyl)-4-hydroxybutanephosphonate

VSC 660




A solution of 2-amino-6-chloro-9-[(2-ethoxy-2-oxo-1,2-oxaphosphorinan-5-yl)methyl]purine (VSC 655; 102 mg, 0.295 mmol) in ethanol (2 ml), water (2 ml), and 2M aqueous sodium hydroxide (1.0 ml, 2 mmol) was kept at 80°C for 3 days, neutralized by addition of weakly acidic Amberlite cation exchange resin, filtered, and evaporated to dryness to give disodium 3-(guanin-9-ylmethyl)-4-hydroxybutanephosphonate.

The starting materials for examples 7 and 8 were prepared as follows:

2-(Acetoxymethyl)-4-bromobutyl acetate

VSC 647




This intermediate was synthesized from 4-(acetoxy)-3-(acetoxymethyl)-butanol according to Literature Procedure. Yield 97% after flash chromatography on silica (ethyl acetate + n-hexane 1+1).

TLC R_f 0.67 (SiO_2 , ethyl acetate + n-hexane 1+1).

^{13}C NMR (CDCl_3 , TMS, 50 MHz): δ 170.30 (COO); 63.44 (CH_2O); 36.27 (CH); 31.67 (Br- CH_2); 30.29 (Br-C- CH_2); 20.51 (CH_3).

Diethyl 4-acetoxy-3-(acetoxymethyl)butanephosphonate

VSC 648




Triethyl phosphite (2.70g, 16.3 mmol) was added with stirring to 2-(acetoxymethyl)-4-bromobutyl acetate (VSC 647, 3.95 g, 14.8 mmol) at 180-190°C and stirring was continued at 190°C for 0.5h. The residue was evaporated in vacuum and kept at ca. 0.1 mB. Flash chromatography on silica with ethyl acetate + ethanol (9+1) yielded 3.36g (70%) of product.

TLC R_f 0.57 (SiO_2 , ethyl acetate + ethanol 9+1).

^{13}C NMR (CDCl_3 , TMSD, 50 MHz): δ 170.37 (COO); 63.22 (CH_2OAc); 61.30/61.18 (CH_2OP , J 6 Hz); 37.58/37.27 (CH, J 16 Hz); 24.11/21.29 ($\text{CH}_2\text{-C-P}$, J 142 Hz); 20.97/20.90 (CH_2P J 4 Hz); 20.46 (CH_3COO); 16.20/16.08, J 6 Hz.

(2-Ethoxy-2-oxo-1,2-oxaphosphorinan-5-yl)methanol (racemic cis-trans mixture)

VSC 650



VSC 648 (1.05; 3.24 mmol) was dissolved in 16 ml of a 0.5 molar solution of sodium ethoxide in ethanol. The solution was warmed to 50°C and then kept at 37°C for 2 h. After evaporation to dryness in vacuum, the residue was extracted with ethyl acetate and purified by flash chromatography on silica with ethyl acetate + ethanol (9+1) as eluent. Yield 0.462 g (74%) of VSC 650 in an isomeric (cis-trans) ratio of 0.36/1.00.


TLC R_f 0.26 (SiO_2 ; ethyl acetate + ethanol 9+1).

^{13}C NMR (CDCl_3 , TMS, 50 MHz); major isomer - minor isomer): δ 72.22/72.08 - 70.64/70.52 (CH_2O in ring, J 6 Hz); 62.18 - 63.64 (CH_2OH); 60.81/60.69 - 61.35/61.23 ($\text{CH}_2\text{-O-P}$, J 6 Hz); 38.87/38.75 - 37.39/37.27 (CH, J 6 Hz); 24.69/24.52 - 23.35/23.18 ($\text{CH}_2\text{-P}$, J 8 Hz); 23.06/20.48 - 21.38/18.80

(CH₂-C-P, J 129 Hz); 16.25/16.15 (CH₃-C-O-P, J 5 Hz).

5-(Bromomethyl)-2-ethoxy-2-oxo-1,2-oxaphosphorinane (racemic cis-trans mixture)

VCS 654




N-Bromosuccinimide (2.67g, 15 mmol) was added in portions to a stirred, ice-chilled solution of 2-ethoxy-2-oxo-1,2-oxaphosphorinan-5-yl)methanol (VSC 650, 1.944 g, 10 mmol) and triphenylphosphine (3.97g, 15 mmol) in 40 ml of dichloromethane, and stirring was continued for 16h at 4°C. After evaporation in vacuum, diethyl ether (50 ml) was added and the mixture shaken and stirred vigorously. The crystallized triphenylphosphine oxide was removed by filtration and washed with several portions of ether. The combined extracts were evaporated to dryness and purified by flash chromatography on silica with ethyl acetate + ethanol (9+1). Yield 1.569 g (61%) of VSC 654 in a cis-trans ratio of 0.7/1.0. TLC Rf 0.57 (SiO₂ ethyl acetate + ethanol 9+1).

¹³C NMR (CDCl₃, TMS, 50 MHz, major isomer - minor isomer): δ 71.76/71.61 (CH₂O in ring, J 6 Hz); 60.74/60.62-61.20/61.08 (CH₂-O-P, J 16 Hz); 37.56/37.44-37.10/36.98 (CH, J 6 Hz); 32.13-31.67 (CH₂Br); 26.66/26.49-25.37/25.23 (CH₂P, J 7 Hz); 22.60/20.02-20.90/18.32 (CH₂-C-P, J 129.4 Hz); 16.13/16.01 (CH₃-C-O-P, J 6.1 Hz).

2-Amino-6-chloro-9-[(2-ethoxy-2-oxo-1,2-oxaphosphorinan-5-yl)methyl] purine and 7 isomer

VSC 655



A mixture of 5-(bromomethyl)-2-etoxy-2-oxo-1,2-oxaphosphorinane (VSC 654; 0.353 g, 1.82 mmol), 2-amino-6-chloropurine (0.50, 2.95 mmol), anhydrous potassium carbonate (0.50 g, 3.62 mmol), and DMF (15 ml) was stirred at room temperature for seven days. Chloroform (30 ml) was added, and after filtration, the solution was evaporated to small volume in vacuum. The residue was purified by flash chromatography on silica (chloroform + methanol 5+1). Yield 0.282 g (45%) as a cis-trans and 7-9 isomeric mixture.

TLC R_F 0.74 and 0.68 for 7 and 9 isomer, respectively (SiO₂, chloroform + methanol 5+1).

¹H NMR (CDCl₃, TMS, 200 MHz): δ 7.80 and 7.76 (s, H8, 7 and 9 isomer); 5.4 (broad s, NH₂); 4.3-4.1 (m, CH₂OP); 4.02 (d, CH₂N); 2.5-2.4 and 2.1-1.7 (m, CHCH₂CH₂P); 1.37 (dt, CH₃-COP).

¹³C NMR (CDCl₃, TMS, 50 MHz): δ 159.38 (C₂); 153.93 (C4); 143.50 (C8); 70.91/70.79-69.94/69.79 (CH₂O in ring, J 7 Hz) 61.79 to 61.45 (2 d, CH₂-O-P, J 7 Hz); 44.35 and 43.25 (CH₂N); 36.68/36.56-35.05/34.93 (CH, J, 6 Hz); 25.88/25.74-24.18/24.04 (CH₂P, J 7 Hz); 22.99/20.41-21.16/18.59 (CH₂-C-P, J 129 Hz); 16.59/16.47 (CH₃-C-O-P, J 6 Hz).

Biological testsTest I Effect of compounds of the formula I on HIV in H9 cells

5

Materials and methods: HIV infection of H9 cells

H9 cells, 105 cells per well on a 24 well plate, suspended in 2 ml RPMI-medium containing 10 % fetal calf serum, 100 μ g/ml
 10 pencillin, 10 μ g/ml streptomycin sulfate and 2 μ g/ml polybrene are exposed to HIV (HTLV-IIIB) and different concentrations of the test compounds. The plates are incubated at 37°C in 5 % CO₂ for 6-7 days. The contents in each well is then homogenized with a pipette and transferred
 15 to a centrifuge tube. After centrifugation for 10 min at 1500 rpm the supernatant is removed and the cell pellet is analyzed by fixing in methanol on glass plates. Human HIV positive serum diluted 1:80 or 1:160 is added and incubated for 30 min at 37°C. The plate is then washed with phosphate-
 20 buffered saline (PBS) containing Ca²⁺ and Mg²⁺. Sheep antihuman conjugate (FITC) is added and after a new incubation the plate is again washed with PBS. Contrast staining is done with Evans blue and after drying the frequency of HIV antigen containing cells is determined in a
 25 microscope. The test result is shown in Table I.

Table I Concentration (μ M) for 50 % inhibition (IC₅₀) of human immuno deficiency virus multiplication in cell culture

30

Compounds	IC ₅₀ M
9-[4-hydroxy-2-(hydroxymethyl)butyl]- guanine (VSA 671)	1-10
35 (-)-9-[4-hydroxy-2-(hydroxymethyl)butyl]- guanine (VSB 647)	0.1-7
(+)-9-[4-hydroxy-2-(hydroxymethyl)butyl]- guanine (VSB 648)	1-5
9-[4-hydroxy-2-(hydroxymethyl)butyl]-	

guanine (VSC 600)

10

Table I shows that the tested compounds are active inhibitors of HIV virus multiplication.

5

Test II Cellular toxicity

H9 cells, 2×10^7 cells per plate, are incubated in RPMI-1640 medium containing 10 % fetal calf serum, 70 mg/l penicillin, 100 mg/l streptomycin and 10 mM hepes, in absence or presence of test compounds. The number of cells per plate is determined after 48 h. Cells incubated in the absence of test compounds then underwent two cell division cycles.

F5000 cells, which are human embryo cells, 1×10^5 cells per plate, are incubated in Eagle's minimal essential medium, supplemented with Earle's salts, non-essential amino acids, 10 % fetal calf serum, 10 mM hepes, 70 mg/l penicillin and 100 mg/l streptomycin, in absence or presence of test compounds. The number of cells per plate is determined after 48 h. Cells incubated in the absence of test compounds underwent one cell division cycle. The results are given as % inhibition of cell multiplication when the concentration of the compounds is 100 μM or 250 μM .

25

Table II Cellular toxicity on H9 and F5000 cells

Compound	% inhibition (concentration μM)	
	H9	F5000
9-[4-hydroxy-2-(hydroxymethyl)-butyl]guanine (VSA 671)	55 (500)	55 (1000)
(-)-9-[4-hydroxy-2-(hydroxymethyl)-butyl]guanine (VSB 647)	5 (100)	
9-[4-hydroxy-2-(hydroxymethyl)-butyl]-adenine (VSB 600)	25 (200)	25 (500)
2-(2-aminopurin-9-yl)methylbutan-1,4-diol (VSB 212)		20 (500) 75 (500)

Table II shows that the concentrations at which the compounds exhibit toxicities, vastly exceed the concentrations needed for 50 % inhibition of HIV multiplications as given in Table I.

5

Test III Oral bioavailability

Oral bioavailability was determined by dosing the animals (cynomologous monkeys and rats) intravenously and orally on separate occasions with the compounds. Blood samples were taken after appropriate intervals for determination of drug level in plasma. Appropriate pharmacokinetic calculations were then carried out based on plasma concentration against time relationship.

15

Table III Oral bioavailability of compound determined as VSA 671

Compound	F* %
<u>Monkey</u>	
9-[4-hydroxy-2-(hydroxymethyl)butyl]guanine (VSA 671)	10
2-(2-aminopurin-9-yl)methylbutane-1,4-diol-diacetate (VSC 610)	32
<u>Rat</u>	
9-[4-hydroxy-2-(hydroxymethyl)butyl]guanine (VSA 671)	11
9-[4-acetoxy-2-(acetoxymethyl)butyl]guanine.HCl (VSC 640)	20
9-[4-propionoxy-2-(propionoxymethyl)butyl]guanine.HCl (VSC 641)	19
2-(2-aminopurin-9-yl)methylbutan-1,4-diol (VSB 212)	26

35

* Plasma AUC (area under curve) of compound relative to AUC after intravenously given VSA 671.

From the table can be seen how the plasma concentration of VSA 671 is significantly increased after VSA 671 has been given as a 6-deoxy prodrug (VSB 212), and ester (VSC 600, VSC 641) or an ester of 6-deoxy prodrug (VSC 610).

5

10

15

20


25

30

35

CLAIMS

1. A compound of the formula




15 wherein:

R¹ is hydrogen, hydroxy, mercapto or amino;

R² is hydrogen, hydroxy, fluoro, chloro or amino;

R³ and R⁴ are independently selected from



or an ether or ester residue thereof, or

25

R³ together with R⁴ is $\begin{array}{c} \text{O} \\ \parallel \\ -\text{P}-\text{O}- \\ | \\ \text{OM} \end{array}$, wherein

M is hydrogen or a pharmaceutically acceptable counterion;

30 and n is 1 or 2; with the proviso that, when R² is amino and R³ and R⁴ are hydroxy, R¹ is not hydroxy and in addition, when n = 1, R¹ is not hydrogen, and pharmaceutically acceptable salts thereof.



35 2. A compound according to claim 1 in the form of an optical isomer.

3. A compound according to claim 1 or 2, wherein R³ and R⁴ are both hydroxy.

4. A compound according to any of claims 1 - 3, wherein R^3 and R^4 as an ether residue is defined as OR^5 , wherein R^5 is C_{1-6} alkyl, arylalkyl optionally substituted with one or more alkoxy, amino, nitrile or sulphamido groups or one or more halogen atoms.

5. A compound according to any of claims 1-3, wherein R^3 and R^4 as an ester residue is derived from a carboxylic acid R^6COOH , a carbonic acid R^7OCO_2H , a double ester of a carbonic acid $R^7CO_2CH(R^8)OCO_2H$, a sulphonic acid R^7SO_2OH , a carbamic acid $R^7NHCOOH$, or a phosphoric acid, wherein R^6 is hydrogen, C_{1-17} alkyl, alkoxyalkyl, arylalkyl or aryl, R^7 is C_{1-17} alkyl, arylalkyl or aryl, R^8 is hydrogen or C_{1-3} alkyl and said aryl and arylalkyl groups optionally can be substituted with one or more alkyl, alkoxy, amino, nitrile, sulphonamido groups or one or more halogen atoms.

6. A compound according to claim 1 or 2, wherein



7. A compound according to any of claims 1-6 for use in therapy.


8. A pharmaceutical composition comprising as active ingredient a compound according to any of claims 1 - 6 and a pharmaceutically acceptable carrier.

9. A method for therapeutic and/or prophylactic treatment of virus infections in an animal or human host in need of treatment, comprising administering an effective amount of a compound of the formula I as defined in any of claims 1 - 6.

10. A method according to claim 9 for treatment of infections caused by herpes viruses.


11. A method according to claim 9 for treatment of infections caused by viruses requiring reverse transcriptase for replication, including human immunodeficiency viruses and hepatitis B virus.

12. A process for preparation of a compound of the formula




wherein R^1 , R^2 , R^3 , R^4 and n are as defined in claim 1, by

A. condensing an acyclic side chain




wherein W is a terminal leaving group, to the N-9 position of a purine derivative



B. imidazole ring closure of a pyrimidine derivative theof the formula

40

5




10

wherein R^{10} is amino or an amino derivative;

C. imidazole ring closure of a furazano-[3,4-d]pyrimidine ring of the formula

15

20




25 and reductive cleavage of the furazane ring to a compound of the formula I, wherein R^1 is amino; or

D. pyrimidine ring closure of an imidazole derivative of the formula

30


35



41

in which processes $R^1 - R^4$ and n are as defined in claim 1 and optionally may be protected by suitable protecting groups, whereby a mixture of optical isomers or a single optical isomer is obtained and a racemic mixture obtained is optionally separated into the optical isomers.

13. Use of a compound of the formula I




wherein:

R^1 is hydrogen, hydroxy, mercapto or amino;

20 R^2 is hydrogen, hydroxy, fluoro, chloro or amino;

R^3 and R^4 are independently selected from



or an ether or ester residue thereof, or

30 R^3 together with R^4 is $\begin{array}{c} \text{O} \\ || \\ -\text{P}-\text{O}- \\ | \\ \text{OH} \end{array}$, wherein

M is hydrogen or a pharmaceutically acceptable counterion; and n is 1 or 2; and pharmaceutically acceptable salts thereof for the manufacture of a medicament for therapeutic and/or prophylactic treatment of the acquired immuno deficiency syndrome and infections caused by viruses requiring reverse transcriptase for replication.

14. Use of a compound of the formula I according to

claim 13 in the form of an optical isomer.

15. Use according to claim 13 or 14 for the treatment of infections caused by HIV-viruses.

5

16. Use according to claim 13 or 14 for the treatment of infections caused by hepatitis B viruses.

10

15

20

25

30

35

INTERNATIONAL SEARCH REPORT

International Application No PCT/SE89/00255

I. CLASSIFICATION OF SUBJECT MATTER (If several classification symbols apply, indicate all) ⁶		
According to International Patent Classification (IPC) or to both National Classification and IPC ⁴		
C 07 D 473/18, 473/32, 473/34, A 61 K 31/52, 31/675, C 07 F 9/65		
II. FIELDS SEARCHED		
Minimum Documentation Searched ⁷		
Classification System	Classification Symbols	
IPC 4	C 07 D; A 61 K; C 07 F	
Documentation Searched other than Minimum Documentation to the Extent that such Documents are Included in the Fields Searched ⁸		
SE, NO, DK, FI classes as above		
III. DOCUMENTS CONSIDERED TO BE RELEVANT ⁹		
Category [*]	Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²	Relevant to Claim No. ¹³
X	EP, A, 0 146 516 (ASTRA LÄKEMEDEL AKTIEBOLAG) 26 June 1985 see example 1, pages 45-48 & WO, 85/02845 GB, 2151622 EP, 0165289 JP, 61500730 US, 4798833	1-5, 7-8, 12-16
X	EP, A, 0 186 640 (ASTRA LÄKEMEDEL AKTIEBOLAG) 2 July 1986 see pages 1-3, claim 6 & JP, 61171481	1-5, 7-8, 12-16
X	Antimicrobial Agents and Chemotherapy, Vol. 30, No. 4, Oct. 1986, pages 598-605, Alf Larsson et al.: "Mode of action, toxicity, pharmacokinetics, and efficacy of some new antiherpesvirus guanosine analogues related to buciclovir", see the whole document	1-5, 7-8, 12-16
.../...		
<div style="display: flex; justify-content: space-between;"> <div style="width: 45%;"> <p>[*] Special categories of cited documents: ¹⁰</p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> </div> <div style="width: 45%;"> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p>"&" document member of the same patent family</p> </div> </div>		
IV. CERTIFICATION		
Date of the Actual Completion of the International Search	Date of Mailing of this International Search Report	
1989-07-14	1989 -07- 21	
International Searching Authority	Signature of Authorised Officer	
Swedish Patent Office	Göran Karlsson	

III. DOCUMENTS CONSIDERED TO BE RELEVANT (CONTINUED FROM THE SECOND SHEET)		
Category*	Citation of Document, with indication, where appropriate, of the relevant passages	Relevant to Claim No
X	Antimicrobial Agents and Chemotherapy, Vol. 31 No. 1, Jan. 1987, pages 76-80, G. Abele et al.: "Inhibiting effect of (RS)-9- β -hydroxy-2-(hydroxymethyl)butyl guanine on varicella-zoster virus replication in cell culture", see the whole document	1-5, 7-8, 12-16
X	EP, A, 0 108 285 (THE WELLCOME FOUNDATION LIMITED) 16 June 1984, see pages 1-3 & GB, 2130204 GB, 2151222 US, 4649140 DE, 3376325 DE, 3376326 AU, 573540 EP, 0158847 JP, 59089682 US, 4544634 US, 4695570 US, 4609662 US, 4745119	1-5, 7-8, 12-16
A	GB, A, 2 134 907 (CESKLOVENSKA AKADEMIE VED) 22 August 1984	1-5, 7-8, 12-16

FURTHER INFORMATION CONTINUED FROM THE SECOND SHEET

V. ☒ OBSERVATIONS WHERE CERTAIN CLAIMS WERE FOUND UNSEARCHABLE ¹

This International search report has not been established in respect of certain claims under Article 17(2) (a) for the following reasons:

1. ☒ Claim numbers 9-11, because they relate to subject matter not required to be searched by this Authority, namely:

A method for treatment of the human or animal body by therapy.

2. ☐ Claim numbers....., because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

3. ☐ Claim numbers....., because they are dependent claims and are not drafted in accordance with the second and third sentences of PCT Rule 6.4(a).

VI. ☐ OBSERVATIONS WHERE UNITY OF INVENTION IS LACKING ²

This International Searching Authority found multiple inventions in this international application as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims of the international application.
2. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims of the international application for which fees were paid, specifically claims:
3. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claim numbers:
4. ☐ As all searchable claims could be searched without effort justifying an additional fee, the International Searching Authority did not invite payment of any additional fee.

Remark on Protest

- ☐ The additional search fees were accompanied by applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☐ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.